Fact CheckerSign in

NCT07874945Not yet recruitingEarly phase 1

Peripheral Vascular Effects of Insulin in Obesity

Source: ClinicalTrials.gov · Last updated 15 Oct 2026

Brief summary (registry, in English)

Successful completion of this project will advance our understanding of the role sympathetic nervous system overactivity plays in driving skeletal muscle malperfusion during hyperinsulinemia and consequently impaired glucose uptake in obesity.

Status (registry)
Not yet recruiting
Phase (registry)
Early phase 1
Study type
Interventional
Enrollment
64 (estimated)
First submitted
4 Oct 2026
Start date
1 Dec 2026
Primary completion date
Jun 2031
Lead sponsor
University of Missouri-Columbia
Diseases
Obesity
NCT number
NCT07874945

What you commit to

  • Study type: Interventional · Early phase 1
  • Planned participants: 64
  • From 1 Dec 2026 to the primary completion date, Jun 2031
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Use of pharmacological therapy for weight loss

Other illness

  • Diabetes or polycystic ovarian syndrome
  • Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease, stroke
  • Nerve/neurologic disease
  • Uncontrolled hypertension (systolic blood pressure \>180 mmHg and/or diastolic blood pressure \>100 mmHg)
  • Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)
  • Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy
  • History of hypersensitivity to nitrates

Other

  • Pregnancy, breastfeeding
  • Unable to provide consent
  • Current smoking, tobacco, nicotine use
  • Body weight change \>10% within the last 6 months
  • Sensitivity to lidocaine

Who the study is looking for

  • \- 18 to 65 years of age
  • Individuals with obesity and comorbid IR
  • BMI 30-45 kg/m2
  • Waist circumference ≥102 cm (men) or ≥88 cm (women)
  • HOMA-IR ≥2.5
    • Healthy normal weight adults
  • BMI 18-25 kg/m2
  • Waist circumference \<94 cm (men) and \<80 cm (women)
  • HOMA-IR \<2

Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.